You have full text access to this OnlineOpen article

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy

  1. Koichi Azuma1,*,
  2. Yoshihiro Komohara2,4,
  3. Tetsuro Sasada5,*,
  4. Yasuhiro Terazaki3,
  5. Jiro Ikeda1,
  6. Tomoaki Hoshino1,
  7. Kyogo Itoh2,
  8. Akira Yamada2,
  9. Hisamichi Aizawa1

Article first published online: 19 JUL 2007

DOI: 10.1111/j.1349-7006.2007.00557.x

Issue

Cancer Science

Cancer Science

Volume 98, Issue 9, pages 1336–1343, September 2007

Additional Information

How to Cite

Azuma, K., Komohara, Y., Sasada, T., Terazaki, Y., Ikeda, J., Hoshino, T., Itoh, K., Yamada, A. and Aizawa, H. (2007), Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Science, 98: 1336–1343. doi: 10.1111/j.1349-7006.2007.00557.x

Author Information

  1. 1

    Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine,

  2. 2

    Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, and

  3. 3

    Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011;

  4. 4

    Department of Cell Pathology, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556;

  5. 5

    Department of Surgery, Kitano Hospital, Tazuke-Kofukai Medical Research Institute, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan

* To whom correspondence should be addressed. E-mail: azuma@med.kurume-u.ac.jp

Publication History

  1. Issue published online: 19 JUL 2007
  2. Article first published online: 19 JUL 2007
  3. (Received March 23, 2007/Revised May 21, 2007/Accepted May 28, 2007)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (636K)

Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs. The authors evaluated whether ERCC1, p53, or TRX expression could predict progression-free and/or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Immunohistochemistry was used to examine the expression of these three proteins in resected lung tumor samples obtained from 67 patients treated with platinum-based chemotherapy against recurrent tumors after curative resection. Immunostaining for ERCC1, p53, and TRX was positive in 29, 35, and 24 patients, respectively. Patients negative for ERCC1 had a significantly longer median progression-free (44 vs 26 weeks, P = 0.0075) and overall (73 vs 44 weeks, P = 0.0006) survival than those positive for ERCC1. Patients negative for p53 expression had a significantly longer median overall (70 vs 62 weeks, P = 0.0289), but not progression-free (37.5 vs 36 weeks, P = 0.2465), survival than those positive for p53 expression. From multivariate analysis, negative ERCC1 expression (hazard ratio [HR] = 1.3740, P = 0.0147) was a significantly favorable factor for progression-free survival, and negative ERCC1 expression (HR = 1.6533, P = 0.0018) and better performance status (HR = 1.9117, P = 0.0017) were significantly favorable factors for overall survival. This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving platinum-based chemotherapy against recurrent tumors after curative resection and can provide critical information for planning personalized chemotherapy. (Cancer Sci 2007; 98: 1336–1343)

View Full Article (HTML) Get PDF (636K)